The proto-oncogene c-fms is overexpressed in endometrial cancer

Gynecol Oncol. 1993 May;49(2):190-6. doi: 10.1006/gyno.1993.1106.

Abstract

Recent studies have shown that macrophage colony-stimulating factor and its receptor c-fms protein are significantly overexpressed in endometrial and ovarian cancers. In the present study, we analyzed the steady-state levels of c-fms mRNA in benign and malignant endometrial tissues by Northern and slot blot analyses. The relative levels of c-fms mRNA were quantified by using a hybridization signal for each sample on Northern blot analysis. Slot blot analysis was used to further quantitate the relative increase in c-fms mRNA in malignant specimens compared to benign specimens. Correlation of c-fms expression in the endometrial cancers was made with traditional prognostic indicators. Secretory endometrium had low levels of c-fms mRNA, whereas the endometrial cancers had the highest levels. Proliferative and hyperplastic endometrium values were intermediate. Comparative assessment of c-fms expression in endometrial cancer relative to other prognostic factors demonstrated greater expression of c-fms in specimens from patients with abnormal DNA ploidy, high-grade lesions, and possibly extrauterine metastases. Our study confirms the overexpression of c-fms in endometrial cancer and demonstrates a positive correlation between the steady-state mRNA levels of c-fms and other select adverse prognostic indicators.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endometrial Neoplasms / genetics*
  • Endometrium / metabolism
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Genes, fms*
  • Humans
  • Ploidies
  • Prognosis
  • Proto-Oncogene Mas
  • RNA, Messenger / analysis
  • RNA, Neoplasm / analysis

Substances

  • MAS1 protein, human
  • Proto-Oncogene Mas
  • RNA, Messenger
  • RNA, Neoplasm